Clinical Trials
22 trialsNCT07341191 2026-05-14
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07261163 2026-05-13
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05852717 2026-05-06
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06784726 2026-05-06
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT07564453 2026-05-04
FLOW
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT06218602 2026-04-15
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06104592 2026-03-31
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07489989 2026-03-24
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06834373 2026-01-28
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
Phase 2 Recruiting
NCT05260957 2025-12-31
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
University of Miami
Phase 2 Recruiting
NCT06854159 2025-09-29
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis
Phase 2 Recruiting
NCT07094477 2025-07-30
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Chinese PLA General Hospital
Phase 2 Active not recruiting
NCT02100891 2025-03-19
STIR
Medical College of Wisconsin
Phase 2 Terminated
NCT06698484 2024-11-21
CAR-T for NHL
National University of Malaysia
Phase 2 Recruiting
NCT05202782 2024-10-16
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT06381830 2024-04-24
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT05783076 2023-08-30
SBRT Plus vNKT for Pancreatic Cancer
Changhai Hospital
Phase 2 Unknown
NCT05312476 2022-04-05
Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01685606 2022-03-04
273
Brown University
Phase 2 Terminated
NCT03068416 2021-10-20
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Phase 2 Completed
NCT04534634 2020-09-01
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown